3 terminated, 1 active not recruiting, 1 completed, 1 enrolling by invitation. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 3, Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow Anetoderma: new trials by email Literature Review of Anetoderma trials Research Report on Anetoderma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study GT005 - Age Related Macular Degeneration (AMD) | Phase 2 | Enrolling by invitation | Gyroscope Therapeutics Limited | 225 | 2022-07-12 | 2026-09-28 |
| HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 255 | 2020-09-28 | 2026-01-28 |
| EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 GT005 - Dry Age-related Macular Degeneration | Phase 2 | Terminated | Gyroscope Therapeutics Limited | 98 | 2019-04-26 | 2026-01-27 |
| FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD GT005, GT005 / Device: Orbit™ Subretinal Delivery System - Dry Age-related Macular Degeneration, Macular Degeneration | Phase 1 / Phase 2 | Terminated | Gyroscope Therapeutics Limited | 56 | 2018-12-17 | 2026-01-28 |
| Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Emixustat - Stargardt Disease, Macular Atrophy | Phase 2 | Completed | Kubota Vision Inc. | 23 | 2017-01-01 | 2021-05-19 |
Geographic Atrophy (4) · Retinal Degeneration (4) · Retinal Diseases (4) · Eye Diseases (3) · Macular Degeneration (2) · Retinitis Pigmentosa (1) · Stargardt Disease (1)
Connective Tissue Diseases (6) · Eye Diseases, Hereditary (6) · Skin Abnormalities (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Eye Diseases (3) · Macular Degeneration (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Retinal Dystrophies (1)
emixustat (1)
Gyroscope Therapeutics Limited (4) · Kubota Vision Inc. (1) · Rubens Camargo Siqueira (1)
United States (5) · United Kingdom (4) · Australia (3) · France (3) · Germany (3) · Spain (3) · Poland (2) · Brazil (1) · Netherlands (1)
PMID 37314061, PMID 33214244, PMID 33750925, PMID 42193355
2019 (1)